Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

  • Munker, Reinhold (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date5/13/21 → 4/24/23